High-Dose Wegovy 7.2mg

A new ceiling just arrived for GLP-1 weight loss treatment, and it changes the conversation about what’s possible without jumping straight to surgery. I’m Dr. Lindsay Ogle, and I’m walking you through brand new FDA-approved high-dose Wegovy dosing that goes up to 7.2 mg of semaglutide, including what we can realistically expect, what could go wrong, and who may benefit most.

We start with the practical basics: how Wegovy dosing has traditionally titrated from 0.25 mg up to 2.4 mg, why each step is usually held for at least four weeks, and how I think about dose increases in real-world obesity medicine. Then I break down the key study behind the new dose, a 72-week randomized double-blind trial comparing 7.2 mg vs 2.4 mg vs placebo. One detail matters a lot for interpreting the results: everyone received lifestyle guidance on nutrition, exercise, sleep, and stress, so we’re truly looking at medication added on top of lifestyle intervention.

From there, we dig into outcomes and tradeoffs. Average total body weight loss reached 18.7% with 7.2 mg vs 15.6% with 2.4 mg, and about 31% of patients on 7.2 mg hit 25% or more weight loss. I also explain why weight loss tends to be lower in people with type 2 diabetes, why early treatment can lead to better results, and what side effects to watch for including the expected GI issues and a notable increase in pins-and-needles sensations at the higher dose.

If this helped you, subscribe, share it with someone you care about, and leave a review so more people can find accurate metabolic health information. What question do you have about high-dose Wegovy 7.2 mg?

Older Obesity Management Medications

GLP-1 Medication Overview

New Obesity Management Medications with Dr. Galindo

When To Increase Your GLP-1 Dose

👩🏼‍⚕️ Live in Missouri? Want to be my patient?
Telehealth clinic: https://missourimetabolichealth.com

🥑 Have questions you want answered on the podcast? Email support@missourimetabolichealth.com

✨Freebies✨
Anti-Obesity Medication Options
How To Prevent Diabetes
Healthy Habits Workbook
Preventative Health Checklist

🤗 Socials:
Instagram: https://www.instagram.com/dr.lindsayogle/
TikTok: https://www.tiktok.com/@dr..lindsay.ogle?_t=8prC4VUQZ5i&_r=1

YouTube: https://www.youtube.com/channel/UCMV0X6U0JLZgRMiNwGtmpeg

Transcript

Welcome And Medical Disclaimer

Dr. Lindsay Ogle, MD 0:00

Welcome to the Modern Metabolic Health Podcast with your host, Dr. Lindsay Ogle, Board Certified Family Medicine and Obesity Medicine Physician. Here we learn how we can treat and prevent modern metabolic conditions such as diabetes, PCOS, fatty liver disease, metabolic syndrome, sleep apnea, and more. We focus on optimizing lifestyle while utilizing safe and effective medical treatments. Please remember that while I am a physician, I am not your physician. Everything discussed here is provided as general medical knowledge and not direct medical advice. Please talk to your doctor about what is best for you. Welcome back to the Modern Metabolic Health Podcast. I'm your host, Dr. Lindsay Ogle, board certified obesity medicine physician. And today we're going to talk about high-dose Weigovi. This is brand new FDA-approved Wigovi dosing, going all the way up to 7.2 milligrams. We're going to dive into what is expected at this higher doses, both positive and negative, and who this medication might be best for. But before we go any further, I want to highlight that I have previously spoke about the other obesity management medications in the past. I think the video is now two or three years old, my initial video where I go over our older, typically more affordable medications like pentermine, kusemia, contrave, and then sometimes we use metformin and vivants for specific indications. I will link that here. And then I had a talk about GLP1 medications in general, so Vigove and Zapbound. I also recently interviewed Dr. Marilyn Galindo about three new obesity management medications, this high-dose Vigovee, as well as Cargisema and Orgfluorgopon, which I could never say correctly. And we touched a little bit also on Redatru Tide, which is further down the line. But if you missed that episode, I will link that as well. And that was an overview of those medication options. But today we're going to take a little bit of a deeper dive specifically into high-dose we GOVI. And I chose to do this because, of course, I'm excited about new obesity management medication options for my patients. But it also was officially FDA approved in March of 2026. And today, as of recording, it's April 1st, 2026, and we are expected to have this medication or this dose available sometime this month. So I wanted to do an overview because by the time that I do release this, the high-dose Weakovi will be available as an option for you or somebody that you love. So when we are talking about Weakovi doses, previously the doses that we had available started with the initial dose, 0.25 milligrams. And everybody should start at this dose and be on it for at least four weeks. And I recently recorded a talk about when to increase your dose of your GLP1 medication. And depending on when this video is released, it may have just that a video may have just been released, or it's going to come in the next week or so. So stay tuned, stay on the lookout for that about the questions that I ask myself when I'm considering increasing the GLP1 dose for my patients. But everyone should be at the initial starting dose for at least a month. They should be at every dose for at least a month, and then sometimes longer depending on a specific situation. But the available Wigovi doses currently are the 0.25 milligram starting dose, then it increases to 0.5, then again to 1 milligram. The next dose is 1.7, and then it is 2.4. And so as of this recording, that is what is available, but pretty soon the doses are going to go up to 7.2 milligrams. And so it's going to increase the dosage to three times what is currently available as the max dose WeGovi. And they did not just make this number up or you know allow this to be available because it sounded great to triple the strength of WeGovi. This was studied extensively. The trial that was released on this was a 72-week randomized double-blind trial that compared this higher dose, the 7.2 milligram Weigov, to the current standard max dose of 2.4 versus placebo. And I really want to take a second here to really highlight something that I don't think everybody in the general public quite understands is that all treatment arms, so the high dose Wigov at 7.2, the um 2.4 milligram dose we go V and placebo, all trial participants got lifestyle guidance along the way. So everybody was educated on what to do from a nutrition standpoint, an exercise standpoint, sleep, you know, mental health, stress management. Everybody got that. But what we were comparing was when you're doing that lifestyle, what is the difference between lifestyle alone versus WeGovi up to 2.4 and then now we go V up to 7.2? And what we found, maybe not surprisingly, is that patients who were on the higher dose WeGovi did on average lose more weight. And what this 72-week study showed is that the 7.2 milligram Wigovi after 72 weeks, the average total body weight loss was 18.7%. This was compared to 15.6% for the 2.4 milligram dose. And then for patients who were not a given Wigovi, they were given placebo, they lost an average of 3.4% of their total body weight. So on average, they did lose weight even without a GLP1 medication without Wigovi, but it was significantly less than the patients who were on Wigovi. I really want to highlight that these are averages, and there were patients that lost a lot more and then lost less. So let's break this down a little bit. So for this 7.2 milligram dose, 31%, so about a third of patients on that dose lost 25% or more of their total body weight. And this is amazing because this is higher than the average for ZeppBound at this current moment, and it is starting to approach metabolic and bariatric surgery. So almost a third of patients who are on the Wigovi 7.2 milligram dose are going to lose one-fourth of their starting body weight or more. This is compared to 15.3% of patients who were on the 2.4 milligram dose of Wigovi, and 0% of patients who were on placebo and doing lifestyle only lost this weight. And I think this is really important to note because on social media and influencers and people who are anti-obesity management medications for whatever reason, um, they really like to promote that everybody can lose weight with lifestyle alone. And it is true that many people can lose some weight, but people who really struggle with the disease of obesity and they have significant weight to lose to achieve and maintain their health, they are going to need actual treatment. They're going to need medication andor metabolic and bariatric surgery. And this study, I think, really highlights that because even though those patients who were given placebo and lifestyle modification they lost on average about 4% of their starting body weight, nobody in that group lost 25% of their total body weight. And there are many people who do need to lose that amount to achieve their health goals. So I really wanted to take the time to highlight that. As with all of our studies for GLP1 medications, we see less weight loss on average for patients who have type 2 diabetes. And this is not fully understood. It's counterintuitive if you ask me, because these medications help with insulin resistance, and we know if we treat insulin resistance, then we can bring down insulin levels, and that can make weight loss easier for most people. But um, people who do have type 2 diabetes and obesity, they tend to, on average, lose less weight. So in a different study that was specifically looking at patients who had type 2 diabetes and they were on the high dose week will be the 7.2 milligrams, their um average shoulder-body weight loss was 13% compared to that 18.7% for patients who did not have type 2 diabetes. So one of the theories that may be for this is that patients who have both type 2 diabetes and obesity, they are just further along in their disease process, which makes it more difficult to manage any chronic condition. The long the further along it is in its process or the more significant it is, the more difficult it'll be to manage. Um, same thing here. Um this also highlights the importance of starting treatment early. So some people have kind of the mindset that they need to, you know, do everything that they, you know, humanly possibly can, um, initiate all the willpower, do all of the diets and courses and treatments other than medication andor surgery before they turn to that, or they maybe feel like they're not quote unquote sick enough to start treatment. These numbers really highlight that you should not wait until you are more sick to start treatment because you may be less responsive to treatment at that time. And so starting um treatment earlier, whether that is lifestyle, medication, or surgery or a combination of you know those three, you're going to have better outcomes in the end. As far as side effects go, not surprisingly, GI side effects were the most common. And we know this from um, you know, other GLP1 medications. Um, one of the ways that they work is they slow the emptying of the stomach. The benefit of that is you feel full on less food and for a longer period of time. So it can help with portion control, can help cut out snacking, but that can lead to GI symptoms like nausea, constipation, acid reflux, uh heartburn. Some people have loose stools or queasiness, um, stomach upset. Those types of symptoms are most common on all GLP1 medications. And we saw the same thing with high-dose weak OV. Specifically for high-dose weak OV, most common side effects were nausea, vomiting, and constipation. But fortunately, serious side effects were fairly uncommon. What was interesting and unique about high-dose weak OV is that in this group, 23% had a pens and needle sensation as a side effect. And this is a much higher percentage of people than we saw previously. Um, previously, for the Weak OV 2.4 milligram dose, that was about 6%. And then in the placebo group, it happened in um 0.5% of people, so almost nobody in the placebo group, uh, 6% in the Wigov 2.4, and then 23% in the high-dose Wigov 7.2 had that pens and needles sensation. Um, so that's something interesting and unique to note that that is happening. So if you are one of the people who do decide to try high-dose Wigov, you can watch for that side effect. Let your provider know if that is happening. So, those are the main things I wanted to highlight with this option, uh with the high-dose Weigovi option. Hi-dose Wigovi is perfect for a patient who has been doing very well on our current Weigovy, and they are at the 2.4 milligram dose, have been there for a while, have seen metabolic improvements, um, have been tolerating it, but they have not yet met their goals. Um, they could now start to titrate up as needed and tolerated, all the way up to that 7.2 milligram dose to help achieve those goals. Um, so again, by the time this is released, um that those doses are going to be available. And please let me know if this is something that you are interested in trying or if you have any questions about this new option that is going to be available. I'd love to hear it. And in the near future, as additional obesity management medications become officially FDA approved, I will release specific episodes to discuss those in you know individually in greater detail. So I look forward to that. I hope you have a wonderful week and take care. Thank you for listening and seeing how you can improve your metabolic health in this modern world. If you found this information helpful, please share with a friend, family member, or colleague. We need to do all we can to combat the dangerous misinformation that is out there. Please subscribe and write a review. This will help others find the podcast so they may also improve their metabolic health. I look forward to our conversation next week.